An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread

NCT02658890 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

627

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer
Melanoma
Non-Small Cell Lung Cancer

Interventions

DRUG: BMS-986205
DRUG: Nivolumab
DRUG: Ipilimumab

Sponsor

Bristol-Myers Squibb